Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Briquilimab

Subcutaneous Administration

OTHER

Placebo

Placebo Comparator

Trial Locations (32)

19103

WITHDRAWN

Site 114, Philadelphia

20815

RECRUITING

Site 104, Chevy Chase

21162

RECRUITING

Site 121, White Marsh

21224

RECRUITING

Site 101, Baltimore

29420

WITHDRAWN

Site 102, North Charleston

33165

RECRUITING

Site 113, Miami

33613

RECRUITING

Site 116, Tampa

35244

RECRUITING

Site 118, Birmingham

45236

RECRUITING

Site 103, Cincinnati

46250

RECRUITING

Site 110, Indianapolis

61761

RECRUITING

Site 124, Springfield

63141

WITHDRAWN

Site 107, St Louis

66210

RECRUITING

Site 122, Overland Park

70508

RECRUITING

Site 123, Lafayette

70808

WITHDRAWN

Site 125, Baton Rouge

72205

RECRUITING

Little Rock Allergy & Asthma Clinical Research Center, Little Rock

75230

WITHDRAWN

Site 112, Dallas

83706

RECRUITING

Site 109, Boise

84107

RECRUITING

Site 111, Murray

92123

RECRUITING

Site 105, San Diego

94538

WITHDRAWN

Site 117, Fremont

98101

RECRUITING

Site 115, Seattle

Unknown

RECRUITING

Site 201, Berlin

RECRUITING

Site 203, Bonn

RECRUITING

Site 211, Buxtehude

RECRUITING

Site 209, Dresden

RECRUITING

Site 208, Frankfurt

RECRUITING

Site 207, Hanover

RECRUITING

Site 206, Lübeck

RECRUITING

Site 202, Marburg

RECRUITING

Site 210, München

RECRUITING

Site 204, Münster

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY